Avalo Therapeutics, Inc. cotiza a 13.24 USD y tiene una capitalización bursátil de $710M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory dis…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.83 | $-0.98 | $-0.37 |
| Estimado | $-0.56 | $-0.62 | $-1.03 | $-1.49 |
| Sorpresa | — | -33.9% | +4.9% | +75.2% |
| Métrica | AVTX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -123601.7% | -38.6% | -123563.1% |
| Net Margin | -132642.4% | -33.6% | -132608.8% |
| FCF Margin | — | -13.9% | — |
| ROE | -94.2% | -40.4% | -53.8% |
| ROA | -67.2% | -32.0% | -35.2% |
| Current Ratio | 8.14 | 2.84 | +5.30 |
| Debt / Equity | — | 0.28 | — |